5:34 PM
 | 
Mar 26, 2013
 |  BC Extra  |  Clinical News

EMA also investigating pancreatic toxicity of antidiabetics

EMA said on Tuesday that it is evaluating the potential pancreatic toxicity of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. The announcement comes just days after FDA said it was evaluating the potential pancreatic toxicity of antidiabetics. Both...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >